ZOGENIX
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
ZOGENIX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zogenix.com
Total Employee:
251+
Status:
Active
Contact:
1-858-259-1165
Total Funding:
1.52 B USD
Technology used in webpage:
Domain Not Resolving EnFlow
Similar Organizations
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
GlaxoSmithKline
GlaxoSmithKline develops and markets products in the areas of pain relief, respiratory, digestive health, oral health, nutrition and skin.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-08-26 | Modis Therapeutics | Modis Therapeutics acquired by Zogenix | 250 M USD |
| 2014-10-27 | Brabant pharma | Brabant pharma acquired by Zogenix | 35 M USD |
Investors List
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Zogenix
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Zogenix
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Venture Round - Zogenix
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Zogenix
Chicago Growth Partners
Chicago Growth Partners investment in Venture Round - Zogenix
Oxford Finance LLC
Oxford Finance LLC investment in Venture Round - Zogenix
Scale Venture Partners
Scale Venture Partners investment in Venture Round - Zogenix
Domain Associates
Domain Associates investment in Venture Round - Zogenix
Clarus Ventures
Clarus Ventures investment in Venture Round - Zogenix
Abingworth
Abingworth investment in Venture Round - Zogenix
Official Site Inspections
http://www.zogenix.com
- Host name: edge.redirect.pizza
- IP address: 89.106.200.1
- Location: Luxembourg
- Latitude: 49.7498
- Longitude: 6.1661
- Timezone: Europe/Luxembourg
More informations about "Zogenix"
UCB to acquire Zogenix
Transaction broadens and builds upon UCB’s role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines …See details»
Zogenix, Inc. - LinkedIn
Mar 2, 2022 Zogenix, Inc. Pharmaceutical Manufacturing Emeryville, California 11,558 followers On 3/2/2022, Zogenix, Inc. was acquired by UCB.See details»
Zogenix - Funding, Financials, Valuation & Investors - Crunchbase
Aug 26, 2019 Zogenix is registered under the ticker NASDAQ:ZGNX . Their stock opened with $4.00 in its Nov 23, 2010 IPO. Zogenix is funded by 10 investors. HealthCare Royalty Partners …See details»
UCB Completes Acquisition of Zogenix, Inc.
Mar 7, 2022 Broadens and builds upon UCB’s role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy Total transaction value …See details»
Zogenix - AnnualReports.com
Zogenix is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS …See details»
UCB to acquire Zogenix
Jan 19, 2022 Copies of the documents filed with the SEC by Zogenix may be obtained at no charge on Zogenix’s internet website at www.zogenix.com or by contacting Zogenix at 5959 …See details»
Zogenix Company Profile - Office Locations, Competitors ... - Craft
Zogenix $81.69 m in annual revenue in FY 2021. See insights on Zogenix including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Zogenix CEO and Key Executive Team | Craft.co
Zogenix's President and Chief Executive Officer, Co-Founder, Director is Stephen J. Farr. Other executives include Gail M. Farfel, Executive Vice President and Chief Development Officer; …See details»
UCB concludes acquisition of biopharma firm Zogenix …
Mar 8, 2022 UCB has concluded the previously announced acquisition of international biopharmaceutical firm Zogenix in a deal valued at up to roughly $1.9bn (€1.7bn). In January, UCB signed a definitive agreement for acquiring …See details»
Zogenix: Business Model, SWOT Analysis, and Competitors 2024
Jan 8, 2024 Zogenix, Inc. is a global pharmaceutical company primarily focused on developing and commercializing therapies for rare diseases. The organization has carved a niche for itself …See details»
Zogenix - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Zogenix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
UCB Completes Acquisition of Zogenix, Inc. | Markets Insider
Mar 7, 2022 BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously annou...See details»
UCB Acquires Zogenix for $1.9 Billion - BioPharm International
UCB announced on Jan. 19, 2022, that it had entered into an agreement to acquire Zogenix, a biopharmaceutical company specializing in therapies for rare diseases, for approximately $1.9 …See details»
UCB Completes Acquisition of Zogenix, Inc. - PR Newswire
Mar 7, 2022 UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living …See details»
UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9 Billion
Jan 19, 2022 Belgian pharmaceutical company UCB SA agreed to buy Zogenix Inc., a U.S. maker of drugs to treat seizures and rare diseases, for as much as $1.9 billion, expanding its …See details»
Zogenix Provides Corporate Update and Reports Fourth Quarter …
Feb 28, 2022 Zogenix, Inc. Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full year. FINTEPLA ® net product sales of $23.5 million in the fourth quarter and $74.7 …See details»
Zogenix Provides Corporate Update and Reports Third Quarter …
FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted ...See details»
Zogenix Provides Corporate Update and Reports Fourth
Feb 28, 2022 Zogenix [email protected]. Investors Brian Ritchie Managing Director, LifeSci Advisors LLC +1 (212) 915-2578 | [email protected]. Media Trish McCall, …See details»
UCB Completes Acquisition of Zogenix, Inc. - PharmiWeb.com
Mar 11, 2022 Pursuant to the terms of the merger agreement, Purchaser merged with and into Zogenix on 7 March 2022. As a result of the merger, Zogenix has become a wholly-owned …See details»